Cargando…

Cutaneous vasculitis in SLE

OBJECTIVES: We determined the temporal association between clinical and serological disease manifestations and development of cutaneous small vessel vasculitis in a large prospective multiethnic cohort. METHODS: Patients with SLE diagnosed according to the Systemic Lupus International Collaborating...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kallas, Romy, Goldman, Daniel, Petri, Michelle A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Epidemiology and Outcomes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509964/ https://www.ncbi.nlm.nih.gov/pubmed/32963114 http://dx.doi.org/10.1136/lupus-2020-000411

Ejemplares similares

Associates and predictors of pleurisy or pericarditis in SLE
por: Ryu, Seungwon, et al.
Publicado: (2017)

Predictors of incident proteinuria among patients with SLE
por: Duarte-García, Alí, et al.
Publicado: (2017)

Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort
por: Davidson, Julie E, et al.
Publicado: (2018)

Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort
por: Györi, Noémi, et al.
Publicado: (2017)

Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic
por: Cardwell, Francesca S, et al.
Publicado: (2022)

Is frailty a relevant concept in SLE?
por: Katz, Patricia P, et al.
Publicado: (2017)

Progression of subclinical and clinical cardiovascular disease in a UK SLE cohort: the role of classic and SLE-related factors
por: Haque, Sahena, et al.
Publicado: (2018)

Strong viral associations with SLE among Filipinos
por: Vista, Evan S, et al.
Publicado: (2017)

Independent association of glucocorticoids with damage accrual in SLE
por: Apostolopoulos, Diane, et al.
Publicado: (2016)

Patient perceptions and preferences of biologic therapies in SLE
por: Lim, S Sam, et al.
Publicado: (2019)

Does the use of corticosteroids and immunosuppressants increase the risk of COVID-19 infection among people with systemic lupus erythematosus?
por: Magder, Laurence S, et al.
Publicado: (2023)

The association between diet and glucocorticoid treatment in patients with SLE
por: Lourdudoss, Cecilia, et al.
Publicado: (2016)

Herpes zoster in SLE: prevalence, incidence and risk factors
por: Kwan, Andrew, et al.
Publicado: (2022)

2021 DORIS definition of remission in SLE: final recommendations from an international task force
por: van Vollenhoven, Ronald F, et al.
Publicado: (2021)

Clinical and histopathological features of myositis in systemic lupus erythematosus
por: Tiniakou, Eleni, et al.
Publicado: (2022)

Evaluation of SLE arthritis using frequency domain optical imaging
por: Marone, Alessandro, et al.
Publicado: (2021)

Which outcome measures in SLE clinical trials best reflect medical judgment?
por: Thanou, Aikaterini, et al.
Publicado: (2014)

Presentation of SLE in UK primary care using the Clinical Practice Research Datalink
por: Nightingale, Alison L, et al.
Publicado: (2017)

Gender differences in SLE: report from a cohort of 417 Caucasian patients
por: Trentin, Francesca, et al.
Publicado: (2023)

Disease duration, age at diagnosis and organ damage are important factors for cardiovascular disease in SLE
por: Nived, Ola, et al.
Publicado: (2020)

Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures
por: Thanou, Aikaterini, et al.
Publicado: (2019)

Development and validation of a simple lupus severity index using ACR criteria for classification of SLE
por: Bello, Ghalib A, et al.
Publicado: (2016)

Exploring lifetime occupational exposure and SLE flare: a patient-focussed pilot study
por: Squance, Marline L, et al.
Publicado: (2014)

Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE with lupus nephritis (LN)
por: Williams-Hall, Rebecca, et al.
Publicado: (2022)

Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE
por: Dobrowolski, Chrisanna, et al.
Publicado: (2023)

Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study
por: Hunnicutt, Jacob N, et al.
Publicado: (2022)

Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE
por: Askanase, Anca D, et al.
Publicado: (2023)

Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey
por: Ngamjanyaporn, Pintip, et al.
Publicado: (2017)

Tacrolimus in non-Asian patients with SLE: a real-life experience from three European centres
por: Tani, Chiara, et al.
Publicado: (2018)

Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis
por: Nakai, Takehiro, et al.
Publicado: (2022)

Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms
por: Eudy, Amanda M, et al.
Publicado: (2022)

Overcoming barriers to recruitment and retention of African–American women with SLE in behavioural interventions: lessons learnt from the WELL study
por: Drenkard, Cristina, et al.
Publicado: (2020)

Assessing cognitive impairment in SLE: examining relationships between resting glucose metabolism and anti-NMDAR antibodies with navigational performance
por: Ploran, Elisabeth, et al.
Publicado: (2019)

Corticosteroid dosing and opioid use are high in patients with SLE and remain elevated after belimumab initiation: a retrospective claims database analysis
por: Birt, Julie A, et al.
Publicado: (2020)

Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara Lupus Cohort
por: Ugarte-Gil, Manuel Francisco, et al.
Publicado: (2022)

Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis
por: Assawasaksakul, Theerada, et al.
Publicado: (2022)

Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE
por: Askanase, Anca D, et al.
Publicado: (2023)

Development of a systemic lupus erythematosus cardiovascular risk equation
por: Petri, Michelle A, et al.
Publicado: (2019)

Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort
por: Giannakou, Ioanna, et al.
Publicado: (2018)

Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus—the Hopkins Lupus Cohort
por: Al Sawah, Sarah, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1jn7qdtg7662ag98o7p8akmp7f